Longer lives, bigger profits: Why I’m bullish on GlaxoSmithKline plc, McCarthy and Stone plc and Carnival plc

Will adding GlaxoSmithKline (LON:GSK), McCarthy and Stone (LON:MCS) and Carnival (LON:CCL) give vitality to your portfolio?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Life expectancy has grown rapidly over recent decades. This is a good thing for us, of course, and it may also be good for our investments. Today, I’ll be looking at three companies that are likely to benefit most.

In need of a health kick?

People will always need medicine, especially as populations (particularly in developing markets) continue to grow and as developed world citizens live longer. With this in mind, adding a pharmaceutical giant to your portfolio may be a shrewd move.

GlaxoSmithKline (LSE:GSK) seems as good a candidate as any. Shares have disappointed over the last few years, dipping to 1,237p last September as a result of concerns surrounding the loss of profit-generating patents. Things now seem to be on the mend. The forthcoming departure of CEO Sir Andrew Witty and some positive figures in the April’s Q1 earnings release has led analysts to start re-evaluating the company and its future prospects.

Glaxo’s share currently trade at 1,410p. While not screamingly cheap with a P/E ratio of 16, the accompanying 80p per share dividend is a fairly decent sticking plaster for now. Although there have been concerns about Glaxo’s ability to cover this payout, these should abate if the company can prove it’s still on the road to recovery when it announces its Q2 results at the end of July.

Time to build a position?

Shares in retirement homes builder, McCarthy and Stone (LSE:MCS) have dropped rather heavily since their peak of 287p in January, perhaps more as a result of general market jitters and the forthcoming EU referendum than anything to do with the company itself. Indeed, the firm’s first set of half-year results since returning to the market last August certainly gave investors reason for cheer.

Reporting a 33% rise in revenue, Chairman John Wright commented that the group had made “strong progress” towards its goal of building and selling more than 3,000 properties every year. Underlying profit before tax increased by 23% to £39.1m with legal completions up by 19% to 923 units. A 1p interim dividend may sound miserly compared to huge payouts offered by other housebuilders, but this dividend is expected to rise rapidly to 6.78p in 2017, covered over three times by earnings.

Having a 70% share in this niche market gives McCarthy and Stone a dominant position over competitors, something that may become even more apparent as a greater proportion of baby boomers downsize. A 26% jump in the order book from £243m to £306m in one year would appear to back this up.

Calm waters ahead 

The imminent maiden voyage of the gigantic Harmony of the Seas cruise liner has made headlines this week. Cruises have appealed to those in retirement but the fact that people are now far more active in their senior years, and given that it’s the fastest growing sector of the global tourism industry, would suggest companies like Carnival (LSE:CCL) will benefit massively now and in the future.

According to Stockopedia, the £27bn cap has a PEG ratio of 0.89 for the current year. Experienced investors will know that anything under 1 signals they’re getting a lot of growth for their money. A dividend yield of just under 2.5%, while fairly average for a mature FTSE100 company, indicates the board is confident of profits being on a steady course.

Paul Summers owns shares in GlaxoSmithKline and McCarthy and Stone.  The Motley Fool has recommended shares in GlaxoSmithKline.  We fools don’t all hold the same views but we all believe that considering a diverse range of insights makes us better investors.

 

More on Investing Articles

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

£5,000 invested in Tesco shares 5 years ago is now worth this much…

Tesco share price growth has been just part of the total profit picture, but can our biggest supermarket handle the…

Read more »

Investing Articles

Here’s why I’m bullish on the FTSE 100 for 2026

There's every chance the FTSE 100 will set new record highs next year. In this article, our Foolish author takes…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Growth Shares

UK interest rates fall again! Here’s why the Barclays share price could struggle

Jon Smith explains why the Bank of England's latest move today could spell trouble for the Barclays share price over…

Read more »

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

2 out-of-favour FTSE 250 stocks set for a potential turnaround in 2026

These famous retail stocks from the FTSE 250 index have crashed in 2025. Here's why 2026 might turn out to…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Down over 30% this year, could these 3 UK shares bounce back in 2026?

Christopher Ruane digs into a trio of UK shares that have performed poorly this year in search of possible bargains…

Read more »

Mature people enjoying time together during road trip
Investing Articles

Yields up to 8.5%! Should I buy even more Legal & General, M&G and Phoenix shares?

Harvey Jones is getting a brilliant rate of dividend income from his Phoenix shares, and a surprising amount of capital…

Read more »

Light trails from traffic moving down The Mound in central Edinburgh, Scotland during December
Investing Articles

Up 7.5% in a week but with P/Es below 8! Are JD Sports Fashion and easyJet shares ready to take off?

easyJet shares have laboured in 2025, but suddenly they're flying. The same goes for JD Sports Fashion. Both still look…

Read more »

US Stock

I think this could be the best no-brainer S&P 500 purchase to consider for 2026

Jon Smith reveals a stock from the S&P 500 that he feels has the biggest potential to outperform the index,…

Read more »